A randomized Phase 2 study evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamics of rozanolixizumab relative to placebo in participants with primary antiphospholipid syndrome.

Administered By

Awarded By

Contributors

Start/End

  • September 20, 2021 - October 31, 2022